Last reviewed 2026-04-23 · How we verify

ISX Group

Vermont Oxford Network · Phase 3 active Small molecule

ISX Group is a Small molecule drug developed by Vermont Oxford Network. It is currently in Phase 3 development. Also known as: Intubation, Surfactant Administration, Extubation to Nasal CPAP. ENSURE..

ISX Group's mechanism of action is not publicly available.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ISX Group
Also known as	Intubation, Surfactant Administration, Extubation to Nasal CPAP. ENSURE.
Sponsor	Vermont Oxford Network
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Unfortunately, there is limited information available on ISX Group's mechanism of action, making it difficult to provide a detailed explanation.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ISX Group CI brief — competitive landscape report
ISX Group updates RSS · CI watch RSS
Vermont Oxford Network portfolio CI

Frequently asked questions about ISX Group

What is ISX Group?

ISX Group is a Small molecule drug developed by Vermont Oxford Network.

How does ISX Group work?

ISX Group's mechanism of action is not publicly available.

Who makes ISX Group?

ISX Group is developed by Vermont Oxford Network (see full Vermont Oxford Network pipeline at /company/vermont-oxford-network).

Is ISX Group also known as anything else?

ISX Group is also known as Intubation, Surfactant Administration, Extubation to Nasal CPAP. ENSURE..

What development phase is ISX Group in?

ISX Group is in Phase 3.

Manufacturer: Vermont Oxford Network — full pipeline
Also known as: Intubation, Surfactant Administration, Extubation to Nasal CPAP. ENSURE.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing